DGAP-News: Biotest AG: Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): Capital Increase
Biotest AG: Biotest AG successfully completes capital increase 2013:
New shares were oversubscribed, Issuing volume amounts to EUR 76
million
26.06.2013 / 12:30
---------------------------------------------------------------------
/
PRESS RELEASE
Biotest AG successfully completes capital increase 2013: New shares were
oversubscribed, Issuing volume amounts to EUR 76 million
Dreieich, June 26, 2013 - During this year's annual shareholders meeting of
Biotest AG, chief executive officer Professor Dr. Gregor Schulz announced a
capital increase to finance the company's expansion strategy. Today Biotest
announces the successful completion of the capital increase: the maximum
amount of 1,461,909 new preference shares at a price of EUR 52 per share
were acquired by shareholders exercising their subscription rights or were
placed with institutional investors due to high interest in the share. Thus
the gross proceeds of the issue amount to EUR 76 million.
Following a roadshow where the management presented reasons for the capital
increase as well as the capacity expansion to potential investors,
equinet Bank - as early as June 10 and within just a few hours - sold all
1,461,909 new preference shares as pre-placements to institutional
investors. The placement was in part subject to claw-back rights of the
company's shareholders. This procedure was possible because OGEL GmbH and
Kreissparkasse Biberach/special funds of Kreissparkasse Biberach declared
that they will not exercise their subscription rights, resulting in approx.
598,000 preference shares being placed without claw-back. Of the remaining
approx. 864,000 shares, Biotest shareholders acquired approx. 52 % of the
shares exercising their subscription rights and approx. 413,000 new
preference shares placed, which were subject to claw-back and for which
subscription rights were not exercised, will be delivered to the
institutional investors.
Thus 1,461,909 bearer preference shares without nominal value (no-par
shares) with a notional interest of EUR 2.56 per share were issued.
Biotest's board of management and supervisory board took all decisions
necessary under the German Stock Corporation Act and filed for registration
of the capital increase with the commercial register.
The stock exchange registration of the new preference shares will
presumably take place on June 28, 2013 and their delivery on July 1, 2013.
The company will then receive the proceeds of the share issue amounting to
EUR 76 million.
Biotest Aktiengesellschaft
The Management Board
Biotest AG
Landsteinerstr. 5
63303 Dreieich
www.biotest.de
ISIN: DE0005227235; DE0005227201
WKN: 522723; 522720
This publication constitutes neither an offer to sell nor a solicitation to
buy or subscribe to securities.
The information contained herein is not for distribution, directly or
indirectly, in or into the United States of America and must not be
distributed to U.S. persons (as defined in Regulation S of the U.S.
Securities Act of 1933, as amended ('Securities Act')) or publications with
a general circulation in the United States of America. This publication
constitutes neither an offer to sell nor a solicitation to buy or subscribe
to securities in the United States of America. The securities have not been
and will not be registered underthe Securities Act and may not be offered
or sold in the United States of America absent registration or an exemption
from registration under the Securities Act. The Issuer does not intend to
register any portion of the offering in the United States of America or to
conduct a public offering of the securities in the United States of
America.
This publication is only addressed to and directed at persons in member
states of the European Economic Area who are 'qualified investors' within
the meaning of Article 2(1)(e) of the Prospectus Directive (Directive
2003/71/EC as amended) ('Qualified Investors'). In addition, in the United
Kingdom, this publication is being distributed only to, and is directed
only at, Qualified Investors who (i) are persons who have professional
experience in matters relating to investments falling within Article 19(5)
of the Financial Services and Markets Act 2000 (Financial Promotion) Order
2005, as amended (the 'Order'), (ii) are high net worth entities falling
within Articles 49(a) to (d) of the Order, or (iii) other persons to whom
it may otherwise lawfully be communicated (all such persons together being
referred to as 'relevant persons'). Any investment or investment activity
to which this publication relates is only available to and will only be
engaged in with (i) in the United Kingdom, relevant persons, and (ii) in
any member state of the European Economic Area other than the United
Kingdom, Qualified Investors. Any other persons who receive this
publication in the European Economic Area should not rely on or act upon
it.
The information contained herein is not for publication or distribution,
directly or indirectly, in or into the United States of America, Canada,
Japan or Australia.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
26.06.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
218187 26.06.2013
Themen in dieser Pressemitteilung:
biotest-ag-biotest-ag-successfully-completes-capital-increase-2013-new-shares-were-oversubscribed
issuing-volume-amounts-to-eur-76-million
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2013 - 12:30 Uhr
Sprache: Deutsch
News-ID 273313
Anzahl Zeichen: 10082
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 481 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Biotest AG successfully completes capital increase 2013: New shares were oversubscribed, Issuing volume amounts to EUR 76 million"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
